Facilitates Oncogenesis in Gastric Cancer Cells by Modulating miR-149 Expression.

Background/aim: Circular RNA (circRNA) is related to gastric carcinogenesis and progression. This study explored the effects of circTCF25 on gastric cancer cell proliferation, migration, invasion, and cancer stem cell markers, as well as the potential network of circTCF25-miR and miR-149.

Materials And Methods: circTCF25 expression was detected in tissue specimens and cells by real-time quantitative reverse transcription polymerase chain reaction.

miR-548 predicts clinical prognosis and functions as a tumor promoter in gastric cancer.

Numerous pieces of evidence have demonstrated the functional role of miR-548 in various cancers. The expression and function of miR-548 in gastric cancer were investigated in the present study. A total of 123 gastric cancer patients were included and provided paired gastric cancer tissues and matched normal tissues.

Crocin inhibits the migration, invasion, and epithelial-mesenchymal transition of gastric cancer cells via miR-320/KLF5/HIF-1α signaling.

The biological activities of crocin, one of the main bioactive compounds of saffron, include anti-inflammatory, antioxidant, antidepressant, and anticancer effects. Crocin has been shown to trigger the apoptosis of gastric cancer cells, but its effect on the metastasis of gastric cancer cells remains unclear. Krüppel-like factor 5 (KLF5) and hypoxia-inducible factor-1α (HIF-1α) are important transcription factors in the development of gastric cancer.

Shugan-decoction relieves visceral hyperalgesia and reduces TRPV1 and SP colon expression.

Aim: To evaluate the therapeutic effect of Shugan-decoction (SGD) on visceral hyperalgesia and colon gene expressions using a rat model.

Methods: Ninety-six adult male Wistar rats were randomized into six equal groups for assessment of SGD effects on psychological stress-induced changes using the classic water avoidance stress (WAS) test. Untreated model rats were exposed to chronic (1 h/d for 10 d consecutive) WAS conditions; experimental treatment model rats were administered with intragastric SGD at 1 h before WAS on consecutive days 4-10 (low-dose: 0.